“Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.”
“Enzalutamide significantly prolonged OS, radiographic PFS and time to PSA progression in both younger and older patients with metastatic castration-resistant prostate cancer, according to a post-hoc analysis of the phase 3 AFFIRM trial.
“The original analysis of the randomized, double blind trial indicated that patients with prostate cancer who previously received docetaxel chemotherapy demonstrated improved median OS when treated with enzalutamide (Xtandi, Astellas Pharma) — an oral androgen receptor inhibitor — compared with patients assigned placebo (18.4 months vs. 13.6 months; HR=0.63; 95% CI, 0.53-0.75).”
“Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference. The combination of estrogen plus progesterone and the use of long-term hormone therapy were associated with the most significant improvements in survival.
“The study was designed to explore the influence of several reproductive and hormonal factors on overall survival of women with non-small cell lung cancer (NSCLC). After adjusting for stage of disease at diagnosis, treatment type (surgery or radiation), smoking status, age, race, and education level, the only factor studied that predicted survival after a diagnosis of NSCLC was use of hormone therapy.”
“Death rates from prostate cancer have fallen by 20% since the early 1990s according to new figures released by Cancer Research UK. At their peak in the early 1990s, there were around 30 deaths per 100,000 men, but this figure has fallen to around 24 deaths per 100,000. The downward trend is largely as a result of new approaches to treating prostate cancer such as earlier, more widespread use of hormone therapy, radical surgery, and radiotherapy, as well as the earlier diagnosis of some cancers linked to the use of the prostate-specific antigen (PSA) test.”
“Treatments that ease hot flashes in menopausal women are not effective against hot flashes in men undergoing hormone therapy for prostate cancer, a new study finds. Hormone therapy in prostate cancer patients reduces levels of male hormones (androgens) to prevent them from reaching prostate cancer cells and stimulating cancer growth. Hot flashes occur in about 80% of prostate cancer patients undergoing hormone therapy.”